更新
10月15日 - ** 制药商Omeros OMER.O股价飙升195.1%，至12.10美元的近10个月高点
** 如果涨势保持，该股将创下有史以来最大单日 百分比涨幅
** 诺和诺德公司（Novo Nordisk）与该公司签署许可协议，获得 (link) 治疗罕见血液和肾脏疾病的实验性药物扎替尼巴特（zaltenibart）的全球使用权。
** OMER有资格获得总额高达21亿美元的资金，包括3.4亿美元的预付款和近期里程碑付款
** 包括本交易日的走势在内，该股今年累计上涨 0.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.